Abstract

In the quest to provide treatment for COVID-19 patients, available therapies that have been approved for other indications but have insufficient evidence of safety and efficacy for use against COVID-19 have been considered. One of the unintended consequences of this approach is the potential creation of shortages, depriving existing patients who are benefiting from products based on their proven indications. Here, a pharmaceutical company outlines their ethical decision-making framework to guide decision-making and ensure equity of access to products.

Authors

Arthur L. Caplan, Joanne Waldstreicher, Karla Childers, Aran Maree

×

Download this citation for these citation managers:

Or, download this citation in these formats:

If you experience problems using these citation formats, send us feedback.

Advertisement